Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Choline chloride injection dose-selection and placebo-controlled study in intestinal failure on long-term parenteral support
2024-519496-26-00Phase 3Authorised
- Sponsor
- Protara Therapeutics
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of choline chloride in intestinal failure (IF) and choline deficiency disease (5 arms), sponsored by Protara Therapeutics. Primary endpoints: Non-compartmental plasma free choline pharmacokinetic parameters, Change in time-matched plasma free choline concentrations and 5 more. Planned start Jul 2025; status: authorised.
02
Drugs
choline chloride
03
Conditions
intestinal failure (IF)choline deficiency disease
Beyond the preview
Go deeper on 2024-519496-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519496-26-00.